<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519204</url>
  </required_header>
  <id_info>
    <org_study_id>VOLBELLA-005</org_study_id>
    <nct_id>NCT03519204</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults</brief_title>
  <official_title>A Randomized, Multicenter, No-treatment-controlled Study of the Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of VOLBELLA with Lidocaine injectable
      gel in Chinese adults seeking lip enhancement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Improvement on the Evaluating Investigator's (EI's) Assessed 5-point Lip Fullness Scale (LFS)</measure>
    <time_frame>Month 3 Post Treatment or Randomization</time_frame>
    <description>Assessed using 5-point Lip Fullness Scale. Scores range from 0=Minimal, to 5= Very Marked.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement based on the Participants's Assessed 5-point LFS</measure>
    <time_frame>Month 3 Post Treatment or Randomization</time_frame>
    <description>Assessed using 5-point Lip Fullness Scale. Scores range from 0=Minimal, to 5= Very Marked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Overall Lip Volume</measure>
    <time_frame>Baseline to Month 3 Post Treatment or Randomization</time_frame>
    <description>As measured by 3-dimensional (3D) photography images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lip Surface Area</measure>
    <time_frame>Baseline to Month 3 Post Treatment or Randomization</time_frame>
    <description>As measured by 3D photography images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Pain Score</measure>
    <time_frame>Up to 30 Days After Each Treatment</time_frame>
    <description>Evaluate pain on an 11-point scale, where 0 is no pain and 10 is the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Injection Site Responses (ISRs)</measure>
    <time_frame>Up to 30 Days After Each Treatment</time_frame>
    <description>Severity and duration of ISRs are obtained using participant safety diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline to Month 12 Post Treatment</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or a participant using an investigational drug, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Lip Enhancement</condition>
  <arm_group>
    <arm_group_label>JUVÉDERM VOLBELLA with Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Juvederm Volbella XC with lidocaine injected into lips at Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No-treatment control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM VOLBELLA with Lidocaine</intervention_name>
    <description>Juvederm Volbella XC with lidocaine injected into lips at Day 1</description>
    <arm_group_label>JUVÉDERM VOLBELLA with Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No-treatment control</intervention_name>
    <description>No-treatment control</description>
    <arm_group_label>No-treatment control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older with an overall baseline LFS score of
             minimal, mild or moderate on the 5-point LFS scale.

          -  Has the ability to follow study instructions and is likely to complete all required
             visits

        Exclusion Criteria:

          -  Has had any facial procedures or trauma that may interfere with the study procedures
             and results

          -  Is on anti-coagulation therapy or other contra indicated treatments

          -  Has current cutaneous inflammatory or infectious processes or lesions in the mouth
             area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Jai</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Develpoment</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Guangzhou Military Command of PLA</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR‐CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

